"The manufacturing alliance with HGS is an excellent strategic partnership for both companies and is representative of Hospira's commitment to meet future demand for high-quality, cost-effective alternatives to proprietary biopharmaceuticals," said John Lane, Vice President, Biologics, Hospira, Inc. "By securing access to HGS' leading-edge technology in late-stage process development and large-scale biopharmaceutical manufacturing capability, we also defer the immediate need to invest in additional Hospira facilities for the manufacture of these biologic products."
In addition to the agreement with Hospira announced today, HGS entered into a marketing services agreement with Eden Biodesign Ltd. in mid-August 2008, under which Eden Biodesign will assist HGS in identifying other large- scale manufacturing and late-stage process development clients.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to
bring innovative drugs to patients with unmet medical needs. The HGS
clinical development pipeline includes novel drugs to treat hepatitis C,
lupus, inhalation anthrax, cancer and other immune-mediate
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved